A securities class action has been filed against Erasca, Inc. in the United States District Court for the Southern District of California on behalf of investors who purchased or acquired the company’s securities between January 14, 2025 and April 26, 2026. The complaint alleges Erasca failed to tell investors that preclinical data for ERAS-0015 relied on improper comparisons with Revolution Medicines, Inc. and exposed the company to potential patent and trade secret claims, leaving defendants without a reasonable basis for positive statements about the drug candidate. The filing points to an April 27, 2026 Form 8-K in which Erasca said it had received a letter from legal counsel for Revolution Medicines alleging that ERAS0015 infringes U.S. Patent No. 12,409,225 and is linked to alleged trade secret misappropriation, while also challenging the company’s public comparisons between ERAS-0015 and RMC-6236. Erasca said it believed the claims were without merit and would contest them. The complaint says the stock fell from $21.49 at the April 24, 2026 close to a $20.70 open on April 27, before ending that day at $19.15. Gainey McKenna & Egleston said investors seeking lead plaintiff status must act by August 10, 2026.